Bind Therapeutics Inc (BIND) 7.01 $BIND
BIND Therapeutics Presents Data Highlighting Ability of Accurins to Control Biodistribution and Accumulate in Target Tissue at AACR Annual Meeting 2015
Business Wire - Wed Apr 22, 7:00AM CDT
--- Data demonstrate optimized drug properties including improved therapeutic index, elevated accumulation in targeted tissue at tumor sites and sustained release -
BIND: 7.01 (-0.30)
BIND Therapeutics (BIND) Looks Good: Stock Adds 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 8:04AM CDT
BIND Therapeutics, Inc. (BIND) was a big mover last session, as the company saw its shares rise over 6% on the day.
AEZS: 0.60 (-0.03), BIND: 7.01 (-0.30)
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 14, 4:58PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
HTBX: 7.71 (-0.64), DOVR: 8.42 (-0.02), STCK: 18.52 (-0.02), CLVS: 85.04 (-1.36), ORMP: 7.25 (-0.10), BIND: 7.01 (-0.30), EGRX: 60.53 (+1.22), VLTC: 15.14 (-1.04), BCLI: 4.29 (-0.09), REPH: 10.71 (-0.78)
Three Small Cap Stocks That Are Being Overlooked By Wall Street
ACCESSWIRE - Wed Apr 08, 6:25PM CDT
NEW YORK, NY / ACCESSWIRE / April 8, 2015 / With extremely volatile equity markets numerous small cap companies have presented incredible upside opportunities for investors. However, countless companies remain unnoticed and forgotten by analysts, journalists, and investors. There are several companies that we have uncovered that merit more attention in our opinion due to underlying fundamental, industry and technical factors. Organovo Holdings, Inc. (NYSE: ONVO), BIND Therapeutics, Inc. (NASDAQ: BIND) and ForceField Energy Inc. (NASDAQ: FNRG), despite their differing industries, present traders and investors with similar factors that are capable of providing incredible upside opportunity.
FNRG: 3.11 (-0.86), ONVO: 5.14 (+0.67), PFE: 34.93 (+0.04), BIND: 7.01 (-0.30)
Bind Therapeutics (BIND) Weak On High Volume
at The Street - Wed Apr 08, 9:03AM CDT
Trade-Ideas LLC identified Bind Therapeutics (BIND) as a weak on high relative volume candidate
BIND: 7.01 (-0.30)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Apr 07, 11:45AM CDT
AMRS: 2.61 (unch), ASPS: 18.07 (+1.32), PBF: 29.60 (+0.40), TOF: 4.12 (-0.03), OCN: 7.68 (+0.14), SYRX: 2.09 (-0.05), CMCM: 23.51 (+1.74), BIND: 7.01 (-0.30), PDII: 1.36 (-0.02), THTI: 0.97 (-0.02), WBAI: 16.75 (-0.46), OCUL: 25.90 (-0.05), QUNR: 49.30 (+0.31), HOFT: 24.00 (unch), CTSO: 7.13 (-0.06), PSTR: 4.78 (+0.07), CBMG: 32.14 (+2.21), ENRJ: 1.75 (+0.05), VPCO: 0.80 (unch), SRSC: 7.81 (-0.15)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Apr 07, 8:13AM CDT
ASPS: 18.07 (+1.32), MY: 3.13 (+0.02), GBX: 64.37 (+0.56), OCN: 7.68 (+0.14), BIND: 7.01 (-0.30), GEL: 47.60 (-0.90), VLTC: 15.14 (-1.04), OCUL: 25.90 (-0.05), BLDP: 2.14 (-0.09), AG: 4.85 (-0.13), CLVS: 85.04 (-1.36), ONVO: 5.14 (+0.67), IGT: 19.88 (-0.02)
BIND Extends Collaboration with Pfizer to Develop Accurins - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 06, 1:00PM CDT
BIND Therapeutics (BIND) has extended its global collaboration with Pfizer Inc. (PFE) to develop and commercialize Accurins.
LCI: 66.45 (-0.28), MRK: 57.69 (+0.03), PFE: 34.93 (+0.04), BIND: 7.01 (-0.30)
Bind +8.7%; Pfizer deal timeline extended
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 5:44PM CDT
PFE: 34.93 (+0.04), BIND: 7.01 (-0.30)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 4:38PM CDT
VSTM: 9.99 (unch), NBL: 51.18 (+0.05), SIGM: 8.36 (+0.29), ARGS: 8.48 (-0.11), IBN: 10.30 (+0.12), ERI: 7.50 (+0.30), SGMS: 12.48 (+0.25), BNDX: 53.90 (-0.10), BIND: 7.01 (-0.30), FPRX: 24.07 (-0.85)
BIND Therapeutics Announces Extension of Global Collaboration with Pfizer Inc. to Develop and Commercialize Multiple Accurins
Business Wire - Thu Apr 02, 3:01PM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced an extension of the terms of its global collaboration with Pfizer Inc. to create Accurins that optimize the therapeutic potential of two molecularly targeted oncology drugs in Pfizer's pipeline. The collaboration was originally established in April 2013 and the timeline for Pfizer to exercise its option to acquire the exclusive license for the first program continues to be September 2015. Both companies agreed to an extension of the timeline for the second program through March 2016.
PFE: 34.93 (+0.04), BIND: 7.01 (-0.30)
Data from Three Abstracts Validating Potential of BIND Therapeutics' Accurins(TM) to be Presented at American Association for Cancer Research Annual Meeting
Business Wire - Wed Mar 18, 3:23PM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, today announced the online availability of three abstracts that will be presented during the April 18-22 American Association of Cancer Research (AACR) Annual Meeting in Philadelphia. The abstracts were published online at www.aacr.org.
BIND: 7.01 (-0.30)
It's Time To Invest In BIND Therapeutics
Stock Doctor - Seeking Alpha - Tue Mar 17, 9:25AM CDT
My biotech investment strategy is simple. I look for companies, which have promising drugs, numerous catalysts on the horizon, undervalued for no apparent reason or have endured a prolonged decline from a trivial event. My recent articles illustrate...
AZN: 73.35 (+0.65), BIND: 7.01 (-0.30)
BIND Therapeutics Presents Data Highlighting Ability of Accurins to Control Biodistribution and Accumulate in Target Tissue at AACR Annual Meeting 2015
Business Wire - Wed Apr 22, 7:00AM CDT
--- Data demonstrate optimized drug properties including improved therapeutic index, elevated accumulation in targeted tissue at tumor sites and sustained release -
BIND: 7.01 (-0.30)
BIND Therapeutics (BIND) Looks Good: Stock Adds 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 8:04AM CDT
BIND Therapeutics, Inc. (BIND) was a big mover last session, as the company saw its shares rise over 6% on the day.
AEZS: 0.60 (-0.03), BIND: 7.01 (-0.30)
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 14, 4:58PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
HTBX: 7.71 (-0.64), DOVR: 8.42 (-0.02), STCK: 18.52 (-0.02), CLVS: 85.04 (-1.36), ORMP: 7.25 (-0.10), BIND: 7.01 (-0.30), EGRX: 60.53 (+1.22), VLTC: 15.14 (-1.04), BCLI: 4.29 (-0.09), REPH: 10.71 (-0.78)
Three Small Cap Stocks That Are Being Overlooked By Wall Street
ACCESSWIRE - Wed Apr 08, 6:25PM CDT
NEW YORK, NY / ACCESSWIRE / April 8, 2015 / With extremely volatile equity markets numerous small cap companies have presented incredible upside opportunities for investors. However, countless companies remain unnoticed and forgotten by analysts, journalists, and investors. There are several companies that we have uncovered that merit more attention in our opinion due to underlying fundamental, industry and technical factors. Organovo Holdings, Inc. (NYSE: ONVO), BIND Therapeutics, Inc. (NASDAQ: BIND) and ForceField Energy Inc. (NASDAQ: FNRG), despite their differing industries, present traders and investors with similar factors that are capable of providing incredible upside opportunity.
FNRG: 3.11 (-0.86), ONVO: 5.14 (+0.67), PFE: 34.93 (+0.04), BIND: 7.01 (-0.30)
Bind Therapeutics (BIND) Weak On High Volume
at The Street - Wed Apr 08, 9:03AM CDT
Trade-Ideas LLC identified Bind Therapeutics (BIND) as a weak on high relative volume candidate
BIND: 7.01 (-0.30)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Apr 07, 11:45AM CDT
AMRS: 2.61 (unch), ASPS: 18.07 (+1.32), PBF: 29.60 (+0.40), TOF: 4.12 (-0.03), OCN: 7.68 (+0.14), SYRX: 2.09 (-0.05), CMCM: 23.51 (+1.74), BIND: 7.01 (-0.30), PDII: 1.36 (-0.02), THTI: 0.97 (-0.02), WBAI: 16.75 (-0.46), OCUL: 25.90 (-0.05), QUNR: 49.30 (+0.31), HOFT: 24.00 (unch), CTSO: 7.13 (-0.06), PSTR: 4.78 (+0.07), CBMG: 32.14 (+2.21), ENRJ: 1.75 (+0.05), VPCO: 0.80 (unch), SRSC: 7.81 (-0.15)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Apr 07, 8:13AM CDT
ASPS: 18.07 (+1.32), MY: 3.13 (+0.02), GBX: 64.37 (+0.56), OCN: 7.68 (+0.14), BIND: 7.01 (-0.30), GEL: 47.60 (-0.90), VLTC: 15.14 (-1.04), OCUL: 25.90 (-0.05), BLDP: 2.14 (-0.09), AG: 4.85 (-0.13), CLVS: 85.04 (-1.36), ONVO: 5.14 (+0.67), IGT: 19.88 (-0.02)
BIND Extends Collaboration with Pfizer to Develop Accurins - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 06, 1:00PM CDT
BIND Therapeutics (BIND) has extended its global collaboration with Pfizer Inc. (PFE) to develop and commercialize Accurins.
LCI: 66.45 (-0.28), MRK: 57.69 (+0.03), PFE: 34.93 (+0.04), BIND: 7.01 (-0.30)
Bind +8.7%; Pfizer deal timeline extended
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 5:44PM CDT
PFE: 34.93 (+0.04), BIND: 7.01 (-0.30)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 4:38PM CDT
VSTM: 9.99 (unch), NBL: 51.18 (+0.05), SIGM: 8.36 (+0.29), ARGS: 8.48 (-0.11), IBN: 10.30 (+0.12), ERI: 7.50 (+0.30), SGMS: 12.48 (+0.25), BNDX: 53.90 (-0.10), BIND: 7.01 (-0.30), FPRX: 24.07 (-0.85)
BIND Therapeutics Announces Extension of Global Collaboration with Pfizer Inc. to Develop and Commercialize Multiple Accurins
Business Wire - Thu Apr 02, 3:01PM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced an extension of the terms of its global collaboration with Pfizer Inc. to create Accurins that optimize the therapeutic potential of two molecularly targeted oncology drugs in Pfizer's pipeline. The collaboration was originally established in April 2013 and the timeline for Pfizer to exercise its option to acquire the exclusive license for the first program continues to be September 2015. Both companies agreed to an extension of the timeline for the second program through March 2016.
PFE: 34.93 (+0.04), BIND: 7.01 (-0.30)
Data from Three Abstracts Validating Potential of BIND Therapeutics' Accurins(TM) to be Presented at American Association for Cancer Research Annual Meeting
Business Wire - Wed Mar 18, 3:23PM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, today announced the online availability of three abstracts that will be presented during the April 18-22 American Association of Cancer Research (AACR) Annual Meeting in Philadelphia. The abstracts were published online at www.aacr.org.
BIND: 7.01 (-0.30)
It's Time To Invest In BIND Therapeutics
Stock Doctor - Seeking Alpha - Tue Mar 17, 9:25AM CDT
My biotech investment strategy is simple. I look for companies, which have promising drugs, numerous catalysts on the horizon, undervalued for no apparent reason or have endured a prolonged decline from a trivial event. My recent articles illustrate...
AZN: 73.35 (+0.65), BIND: 7.01 (-0.30)
